Otonomy (OTIC) Provides Update on Clinical Trials, Development Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St set for higher open as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Otonomy Provides Update on Clinical Trials and Development Programs
June 15, 2020 4:05 PM EDTResults from Phase 3 trial of OTIVIDEX® in Ménières disease expected in first quarter of 2021Results from Phase 1/2 trial of OTO-313 in tinnitus expected in July 2020Results from Phase 1/2 trial of OTO-413 in hearing loss expected in fourth quarter of 2020Current capital funds operations through all clinical trial readouts
Conference call and webcast today at 4:30 p.m. ET
SAN DIEGO, June 15, 2020 (GLOBE NEWSWIRE) -- Otonomy,... More
